肿瘤微环境与肿瘤免疫治疗的研究现状

doi:10.16139/j.1007-9610.2018.03.011

摘要/Abstract

中图分类号:

R730.51

范逸群, 柏斗胜, 蒋国庆, 张弛. 肿瘤微环境与肿瘤免疫治疗的研究现状[J]. 外科理论与实践, 2018, 23(03): 236-240.

[1] Paget S.The distribution of secondary growths in cancer of the breast. 1889[J]. Cancer Metastasis Rev,1989,8(2):98-101.
[2] Junttila MR, de Sauvage FJ. Influence of tumour microen-vironment heterogeneity on therapeutic response[J]. Nature,2013,501(7467):346-354.
[3] Miller JF, Sadelain M.The journey from discoveries in fundamental immunology to cancer immunotherapy[J]. Cancer Cell,2015,27(4):439-449.
[4] Riaz N, Havel JJ, Makarov V, et al.Tumor and microenvironment evolution during immunotherapy with nivolu-mab[J]. Cell,2017,171(4):934-949.
[5] Thomas PD, Kahn M.Kat3 coactivators in somatic stem cells and cancer stem cells: biological roles, evolution, and pharmacologic manipulation[J]. Cell Biol Toxicol,2016,32(1):61-81.
[6] Plitas G, Konopacki C, Wu K, et al.Regulatory T cells exhibit distinct features in human breast cancer[J]. Immunity,2016,45(5):1122-1134.
[7] Nishikawa H, Sakaguchi S.Regulatory T cells in cancer immunotherapy[J]. Rinsho Ketsueki,2014,55(10):2183-2189.
[8] Zitvogel L, Tanchot C, Granier C, et al.Following up tumor-specific regulatory T cells in cancer patients[J]. Oncoimmunology,2013,2(7):e25444.
[9] Sander FE, Nilsson M, Rydström A, et al.Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy[J]. Cancer Immunol Immunother,2017,66(11):1473-1484.
[10] Qian BZ, Li J, Zhang H, et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis[J]. Nature,2011,475(7355):222-225.
[11] Hao NB, Lu MH, Fan YH, et al.Macrophages in tumor microenvironments and the progression of tumors[J]. Clin Dev Immunol,2012,2012:948098.
[12] Janols H, Bergenfelz C, Allaoui R, et al.A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases[J]. J Leukoc Biol,2014,96(5):685-693.
[13] Yu J, Du W, Yan F, et al.Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer[J]. J Immunol,2013,190(7):3783-3797.
[14] Ortiz ML, Lu L, Ramachandran I, et al.Myeloid-derived suppressor cells in the development of lung cancer[J]. Cancer Immunol Res,2014,2(1):50-58.
[15] Lee KW, Yeo SY, Sung CO, et al.Twist1 is a key regulator of cancer-associated fibroblasts[J]. Cancer Res,2015, 75(1):73-85.
[16] Polanska UM, Orimo A.Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells[J]. J Cell Physiol,2013,228(8):1651-1657.
[17] Olumi AF, Grossfeld GD, Hayward SW, et al.Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium[J]. Cancer Res,1999, 59(19):5002-5011.
[18] Underwood TJ, Hayden AL, Derouet M, et al.Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma[J]. J Pathol,2015,235(3):466-477.
[19] Richards KE, Zeleniak AE, Fishel ML, et al.Cancer-associated fibroblast exosomes regulate survival and proli-feration of pancreatic cancer cells[J]. Oncogene,2017,36(13):1770-1778.
[20] Palazon A, Tyrakis PA, Macias D, et al.An hIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression[J]. Cancer Cell,2017,32(5):669-683.
[21] Viallard C, Larrivee B.Tumor angiogenesis and vascular normalization: alternative therapeutic targets[J]. Angiogenesis,2017,20(4):409-426.
[22] Rofstad EK, Galappathi K, Mathiesen BS.Tumor interstitial fluid pressure - a link between tumor hypoxia, microvascular density, and lymph node metastasis[J]. Neoplasia,2014,16(7):586-594.
[23] Coley WB. II. Contribution to the knowledge of sarcoma[J]. Ann Surg,1891,14(3):199-220.
[24] McNutt M. Cancer immunotherapy[J]. Science,2013,342(6165):1417.
[25] Rosenberg SA, Packard BS, Aebersold PM, et al.Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report[J]. N Engl J Med,1988,319(25):1676-1680.
[26] Rosenberg SA, Restifo NP, Yang JC, et al.Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer,2008,8(4):299-308.
[27] Lawrence MS, Stojanov P, Polak P, et al.Mutational he-terogeneity in cancer and the search for new cancer-asso-ciated genes[J]. Nature,2013,499(7457):214-218.
[28] Ali SA, Shi V, Maric I, et al.T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood,2016,128(13):1688-1700.
[29] Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J]. Sci Transl Med, 2015,7(303):303ra139.
[30] Brown CE, Alizadeh D, Starr R, et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med,2016,375(26):2561-2569.
[31] Xia AL, Wang XC, Lu YJ, et al.Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities[J]. Oncotarget,2017,8(52):90521-90531.
[32] Sharma P, Hu-Lieskovan S, Wargo JA, et al.Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell,2017,168(4):707-723.
[33] Schadendorf D, Hodi FS, Robert C, et al.Pooled analysis of long-term survival data from phase Ⅱ and phaseⅢ trials of ipilimumab in unresectable or metastatic melanoma[J]. J Clin Oncol,2015,33(17):1889-1894.
[34] Friedman CF, Proverbs-Singh TA, Postow MA.Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review[J]. JAMA Oncol,2016,2(10):1346-1353.
[35] Sharpe AH, Pauken KE.The diverse functions of the PD1 inhibitory pathway[J]. Nat Rev Immunol,2017,18(3):153-167.
[36] Sharma P, Allison JP.The future of immune check point therapy[J]. Science,2015,348(6230):56-61.
[37] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus Ipilimumab in advanced melanoma[J]. N Engl J Med,2015,372(26):2521-2532.
[38] Pauken KE, Sammons MA, Odosizzi PM, et al.Epigene-tic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade[J]. Science,2016,354(6316):1160-1165.
[39] Luke JJ, Flaherty KT, Ribas A, et al.Targeted agents and immunotherapies: optimizing outcomes in melanoma[J]. Nat Rev Clin Oncol,2017,14(8):463-482.
[40] Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with pla-tinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial[J]. Lancet,2017,391(10122):748-757.
[41] Balar AV, Galsky MD, Rosenberg JE, et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet,2017,389(10064):67-76.
[42] Miao D, Margolis CA, Gao W, et al.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J]. Science,2018,359(6377):801-806.
[43] Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.Over-all survival with combined nivolumab and Ipilimumab in advanced melanoma[J]. N Engl J Med,2017,377(14):1345-1356.
[44] Herrera FG, Bourhis SJ, Coukos G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin,2017,67(1):65-85.
[45] Lee JM, Cimino-Mathews A, Peer CJ, et al.Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women′s cancers: A dose-escalation, phaseⅠstudy[J]. J Clin Oncol,2017,35(19):2193-2202.
[46] Govindan R, Szczesna A, Ahn MJ, et al.Phase Ⅲ trial of Ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer[J]. J Clin Oncol,2017,35(30):3449-3457.
[47] Matson V, Fessler J, Bao R, et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J]. Science,2018,359(6371):104-108.
[48] Gopalakrishnan V, Spencer CN, Nezi L, et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science,2018,359(6371):97-103.

肿瘤微环境与肿瘤免疫治疗的研究现状

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱芳　徐喆　王先明　宋达疆　李赞　何建怀　屈洪波. 乳腺癌根治术后即刻行扩大背阔肌肌皮瓣乳房再造50例分析[J]. 组织工程与重建外科杂志, 2022, 18(5): 377-.
[2]	刘淼, 沈燕, 傅晓红, 胡姣姣, 陈庆庆, 应涛. 常规超声和超声造影检查不同大小病灶乳腺癌的比较研究[J]. 外科理论与实践, 2022, 27(3): 229-233.
[3]	钟民衎　崔锡炜　顾斌　李青峰　王智超. Ⅰ型神经纤维瘤病相关眼眶-眶周型丛状神经纤维瘤的临床治疗进展[J]. 组织工程与重建外科杂志, 2022, 18(2): 179-.
[4]	潘睿忻综述, 陈小松, 沈坤炜审校. 循环肿瘤DNA和循环肿瘤细胞检测乳腺癌微小残留病灶的研究[J]. 外科理论与实践, 2022, 27(05): 463-467.
[5]	马雪菲, 王学锋, 王侃侃. 浆细胞瘤变异体易位1和MYC基因在泛癌中的表达及生存期预测价值分析[J]. 诊断学理论与实践, 2022, 21(04): 490-496.
[6]	何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[7]	李为光, 孙蕴伟, 孙菁, 张本炎, 王华枫, 钱爱华. 直径≤1 cm的直肠神经分泌肿瘤2种内镜治疗方法的比较[J]. 内科理论与实践, 2022, 17(04): 289-294.
[8]	郭良奇, 严志龙, 张谋成. 腹腔镜经胃腔手术治疗胃黏膜下肿瘤和早期胃癌[J]. 外科理论与实践, 2022, 27(04): 380-383.
[9]	车稳, 柳蒋书, 陈晓炎, 王朝夫, 袁菲, 王璇. 肺混合性鳞状细胞和腺性乳头状瘤2例临床病理特征及冷冻切片病理诊断误诊分析[J]. 诊断学理论与实践, 2022, 21(04): 476-481.
[10]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[11]	管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[12]	汤钊猷. 中华哲学思维对肝癌治疗的启迪[J]. 外科理论与实践, 2022, 27(02): 93-94.
[13]	杨伯文, 姜美娇, 陈慧. 超声IOTA简单法鉴别诊断卵巢肿瘤良恶性的临床研究[J]. 诊断学理论与实践, 2022, 21(01): 74-79.
[14]	史逸华, 吉顺荣, 徐晓武, 虞先濬. 保留功能的微创胰腺肿瘤剜除术技术要点及思考[J]. 外科理论与实践, 2022, 27(01): 14-18.
[15]	李骥, 傅德良, 倪泉兴. 胰腺囊性肿瘤的手术干预决策与局部剜除术[J]. 外科理论与实践, 2022, 27(01): 19-21.